ArticleCureus2026
Livedoid Vasculopathy Mimicking Rheumatoid Vasculitis in a Patient With Active Rheumatoid Arthritis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Livedoid vasculopathy (LV) is a rare thrombo-occlusive disorder of the dermal microcirculation that may clinically resemble inflammatory vasculitis. In patients with rheumatoid arthritis (RA), the development of painful lower extremity ulcers often raises concern for rheumatoid vasculitis, making histopathological evaluation essential for accurate diagnosis and treatment selection. We present a case of a 45-year-old man with an eight-year history of seropositive RA receiving methotrexate, sulfasalazine, and baricitinib who developed painful lower extremity ulcers, edema, and episcleritis in the setting of high disease activity (Disease Activity Score 28 using C-reactive protein {DAS28-CRP} of 6.23). Given the suspicion of rheumatoid vasculitis, an extensive diagnostic workup was performed. Laboratory studies demonstrated elevated inflammatory markers and negative antineutrophil cytoplasmic antibodies. Skin biopsy revealed vascular wall hyalinization, luminal obliteration, and fibrin thrombi in the absence of inflammatory infiltrates or fibrinoid necrosis, establishing the diagnosis of livedoid vasculopathy. Treatment with systemic glucocorticoids and rituximab, administered according to the standard rheumatoid arthritis regimen, resulted in partial improvement in ocular inflammation, joint symptoms, and cutaneous ulceration. Anticoagulant therapy was not initiated because treatment escalation was primarily directed toward uncontrolled rheumatoid arthritis and severe extra-articular manifestations. Histopathological examination demonstrated vascular wall hyalinization, luminal obliteration, and fibrin thrombi in the absence of significant vascular inflammation or fibrinoid necrosis, establishing the diagnosis of livedoid vasculopathy and excluding rheumatoid vasculitis. Although initial clinical improvement was observed, recurrent ocular symptoms and persistent lower extremity ulceration developed following interruption of biologic therapy. Histopathological confirmation demonstrating thrombotic microvascular occlusion without vascular inflammation was essential for establishing the diagnosis and avoiding misclassification as rheumatoid vasculitis. This case highlights the importance of tissue diagnosis in patients with RA presenting with ulcerative cutaneous lesions and emphasizes the need to consider livedoid vasculopathy in the differential diagnosis of suspected rheumatoid vasculitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.